Defibrotide for Sickle Cell Disease

"Presently, 4 clinical trials are evaluating the efficacy of Defibrotide. Unfortunately, none of these studies have reached Phase 3 yet. 9 medical sites scattered around Boston, Massachusetts host these investigations."

"This medical trial seeks to enrol 20 individuals aged between 2 and 40 who are suffering from acute chest syndrome. Eligible patients must possess two or more of the following symptoms: fever, respiratory discomfort, coughing, rapid breathing for their age group, pulmonary infiltration (evidenced by X-ray/CT scan) as well as a decreased oxygen saturation with or without supplemental O2; additionally, female participants within childbearing years will need to submit a negative pregnancy test result."

"According to the requirements, potential trial subjects must be between 2 and 40 years old. 501 trials are available for minors while 1066 are aimed at senior citizens."

"Per clinicaltrials.gov, this inquiry is not presently enrolling patients. The experiment commenced on the 12th of January 2018 and was last revised on 24th October 2022; nonetheless, at present there are 1,577 other medical trials actively recruiting participants."

"At the present moment, this clinical trial is not recruiting. When it was originally listed on December 1st 2018, its last update occured on October 24th 2022. For those interested in similar trials, 1573 studies are enrolling patients dealing with acute chest syndrome and 4 Defibrotide related ones as well."

"The safety of Defibrotide was assessed as a 2, since this clinical trial is still at Phase 2 and has yet to provide data on efficacy."